![Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0360-y/MediaObjects/41416_2018_360_Fig1_HTML.png)
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer
![A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ] A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2019/7837/1/fig-2-2x.jpg)
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]
![Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2021-1054/asset/images/medium/figure2.gif)
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology
![Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine | Journal of Hematology & Oncology | Full Text Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13045-019-0835-1/MediaObjects/13045_2019_835_Fig4_HTML.png)
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine | Journal of Hematology & Oncology | Full Text
![Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial | Journal of Nuclear Medicine Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2024/01/10/jnumed.123.266211/F1.large.jpg)
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial | Journal of Nuclear Medicine
![Improved Overall Survival with Warfarin Compared with Direct Oral Anticoagulants in Cancer-associated Venous Thromboembolism: A SEER-medicare Analysis - ISTH Congress Abstracts Improved Overall Survival with Warfarin Compared with Direct Oral Anticoagulants in Cancer-associated Venous Thromboembolism: A SEER-medicare Analysis - ISTH Congress Abstracts](https://abstracts.isth.org/wp-content/uploads/2021/06/307_results_1.png)
Improved Overall Survival with Warfarin Compared with Direct Oral Anticoagulants in Cancer-associated Venous Thromboembolism: A SEER-medicare Analysis - ISTH Congress Abstracts
![Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database | BMC Medicine | Full Text Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database | BMC Medicine | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12916-023-02754-5/MediaObjects/12916_2023_2754_Fig4_HTML.png)
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database | BMC Medicine | Full Text
![A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/0fbe43e7-b69c-43d2-bff9-10ce650542f3/gr1.jpg)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
![Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/356259194/figure/fig2/AS:1091002400022593@1637126650745/Overall-survival-plot-Kaplan-Meier-curve-is-shown-for-overall-survival-in-patients-with.png)
Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig1_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/71691e58-7199-4c54-b26a-fcd5317e2915/gr1_lrg.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.19.00934/asset/images/large/jco.19.00934f1.jpeg)
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology
![Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial | Journal of Clinical Oncology Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2016.71.8023/asset/images/large/jco.2016.71.8023f2.jpeg)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial | Journal of Clinical Oncology
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/734a0236-aae1-490d-bbfe-b8cf04ab02e7/ga1.jpg)